DE-Bochum-RUB
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schroers, Roland
NCT04464434 / 2019-004718-32: Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

Recruiting
4
50
Europe
Upfront autologous HSCT
UMC Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development, Boehringer Ingelheim, Miltenyi Biotec, Inc.
Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma, Scleroderma, Diffuse, Autologous Stem Cell Transplantation, Cyclophosphamide, Mycophenolate Mofetil, Treatment Strategy
09/25
10/30
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
12/24
06/33
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Recruiting
3
650
Europe
Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation
University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland
Acute Myeloid Leukemia, Myelodysplastic Syndromes
02/25
02/31
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/27
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
125
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
04/25
09/28
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44
Schroers, R
NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Not yet recruiting
3
415
Europe
Revumenib, Placebo
Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network
Acute Myeloid Leukemia, Adult
05/28
05/31

Download Options